journal
MENU ▼
Read by QxMD icon Read
search

Oncology (Williston Park, NY)

journal
https://read.qxmd.com/read/30731018/vitamin-d-and-omega-3-supplements-for-preventing-cancer-and-other-chronic-diseases
#1
JoAnn Manson
No abstract text is available yet for this article.
January 17, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30731017/pathologic-hip-fracture-in-a-49-year-old-man-with-widespread-metastatic-sclerotic-bone-lesions
#2
Mehmet Sitki Copur, Adam Horn, Pornchai Jonglertham
No abstract text is available yet for this article.
January 17, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30731016/the-emerging-profile-of-immunotherapy-approaches-in-the-treatment-of-aml
#3
Naval Daver
No abstract text is available yet for this article.
January 17, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30731015/management-of-neutropenic-toxicity-from-cdk4-6-inhibitors
#4
Kristina Frinzi Byers
No abstract text is available yet for this article.
January 17, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30731014/current-strategies-for-the-management-of-locoregional-breast-cancer-recurrence
#5
Irene L Wapnir, Atif Khan
Advances in the treatment of breast cancer have decreased the rate of isolated locoregional recurrences (ILRRs) over time. Surgery, radiation therapy, and systemic therapies are used to manage these failure events and their associated poor prognosis. Operable ipsilateral breast tumor recurrences (IBTRs) are treated by either salvage mastectomy or, in select cases, repeat lumpectomy. Axillary nodal recurrences and postmastectomy chest wall relapses are commonly amenable to surgical resection, too. Repeat sentinel node mapping may be undertaken after IBTRs and chest wall recurrences...
January 17, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30731013/current-and-future-landscape-of-immune-checkpoint-inhibitors-in-urothelial-cancer
#6
REVIEW
Omar Alhalabi, Amishi Y Shah, Emily A Lemke, Jianjun Gao
Immune checkpoint inhibitors have revolutionized the field of oncology, providing a novel mechanism for anticancer therapy. Programmed death 1-targeting antibodies pembrolizumab and nivolumab and programmed death ligand 1 (PD-L1)-targeting antibodies atezolizumab, durvalumab, and avelumab have been approved for use in advanced urothelial cancer in the post-platinum setting or in the upfront setting in platinum-ineligible patients. While this represents a significant step forward in management of urothelial cancers, most patients do not have an objective response to these therapies...
January 17, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30731012/oncology-conference-highlights-q4
#7
Jennifer Leavitt, Traci DeVito, Naveed Saleh
No abstract text is available yet for this article.
January 17, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30731011/key-advances-in-oncology-2018
#8
Traci DeVito, Jennifer Leavitt, Naveed Saleh
No abstract text is available yet for this article.
January 17, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30632133/counterpoint-prostate-cancer-genomic-analysis-routine-or-research-only
#9
W Kevin Kelly, Karen E Knudsen
No abstract text is available yet for this article.
December 17, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30632132/point-prostate-cancer-genomic-analysis-routine-or-research-only
#10
Brandon Bernard, Thomas W Flaig
No abstract text is available yet for this article.
December 17, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30632131/identifying-molecular-markers-of-relapse-in-myelodysplastic-syndrome
#11
Meagan A Jacoby, Matthew Walter
No abstract text is available yet for this article.
December 17, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30632130/immunotherapeutic-approaches-to-the-management-of-head-and-neck-cancer
#12
Xinyu Nan, Kathryn A Gold, Ezra Cohen
The two programmed death 1 checkpoint inhibitors nivolumab and pembrolizumab are approved by the US Food and Drug Administration as second-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Based on the existing data, the effectiveness of these two drugs is similar in this setting. When choosing between them, the decision should be individualized and can be determined by patient and provider preferences, as well as scheduling. Testing for tumor programmed death ligand 1 (PD-L1) and human papillomavirus status is not required for use of these checkpoint inhibitors in the second-line setting, but the level of tumor PD-L1 expression can be useful for decision making in special situations...
December 17, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30632129/gonadotropin-releasing-hormone-antagonists-in-prostate-cancer
#13
REVIEW
Adam S Kittai, Jessica Blank, Julie N Graff
Androgen deprivation therapy (ADT) comes in several forms, such as surgical castration or medical castration using gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist therapy. ADT is a critical treatment for high-risk and metastatic prostate cancer. There are important differences between GnRH agonists and antagonists. Here we review the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix. We also comment on the potential risks and benefits of degarelix, particularly when it comes to cardiovascular health...
December 17, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30632128/mechanisms-and-treatment-for-cancer-and-chemotherapy-related-cognitive-impairment-in-survivors-of-non-cns-malignancies
#14
REVIEW
Ni-Chun Chung, Adam K Walker, Haryana M Dhillon, Janette L Vardy
Up to 70% of survivors of adult-onset, non-central nervous system (CNS) solid tumors report cognitive symptoms, and approximately 30% have impairment on formal neuropsychological testing. The etiology of the impairment is unknown. There is a lack of robust evidence on how to prevent or treat cancer-related cognitive impairment (CRCI). Here, we review the evidence for the putative mechanisms of CRCI by examining clinical and preclinical models, primarily those associated with chemotherapy. Pharmacologic and nonpharmacologic options for treating CRCI are discussed based on the best evidence available...
December 17, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30632127/strategies-for-the-optimal-management-of-dyspnea-in-cancer-patients-with-advanced-illness
#15
Mona S Patel
Dyspnea in cancer patients can lead to significant deleterious effects. There are multiple conditions that can cause dyspnea. It is important to determine which of these causes are potentially reversible and treatable, so that they can be promptly addressed. Both pharmacologic and nonpharmacologic approaches should be used to treat this difficult condition. As patients advance in their illness, palliative treatments can be considered, such as low-dose opioids, oxygen therapy, and treatments directed at anxiety relief...
December 17, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30474106/atrial-fibrillation-considerations-for-the-use-of-btk-inhibitors
#16
Kelly Valla
No abstract text is available yet for this article.
November 15, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30474105/management-of-metastatic-prostate-cancer-in-frail-elderly-patients
#17
Elizabeth R Kessler
As the world population ages, we can expect to care for an increasing number of older cancer patients. Prostate cancer is inherently a condition that affects patients of advanced age. In caring for these patients who have advanced prostate cancer, it is important to first assess the health status of the patient and his goals of care. As this is established, likely through a geriatric assessment, this will inform how to modify or mold the treatment plan to fit a patient's needs and vulnerabilities. These vulnerabilities may surface as patients undergo treatment such as androgen deprivation therapy-the backbone of systemic therapy for advanced disease...
November 15, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30474104/bone-targeted-therapy-in-early-breast-cancer
#18
Katarzyna J Jerzak, Jacques Raphael, Danielle N Desautels, Phillip S Blanchette, Ivan Tyono, Kathleen I Pritchard
Aromatase inhibitors (AIs) play an important role in the adjuvant treatment of hormone receptor-positive breast cancer, but they are associated with bone loss and increased fracture risk. Although several guidelines for the management of osteoporosis and osteopenia exist, their algorithms do not account for the use of AIs. In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.
November 15, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30474103/role-of-temozolomide-in-the-treatment-of-cancers-involving-the-central-nervous-system
#19
REVIEW
Karisa C Schreck, Stuart A Grossman
Temozolomide has been available to oncologists for over 30 years. During this time, it has become an integral part of standard therapy in patients with high-grade gliomas. Given its ability to traverse the blood-brain barrier, temozolomide has also been evaluated in other cancers that involve the central nervous system (CNS). We review its role in the management of patients with primary brain tumors, brain metastases, leptomeningeal carcinomatosis, and other selected CNS cancers. There is strong evidence that temozolomide is effective in patients with high-grade astrocytomas and oligodendrogliomas...
November 15, 2018: Oncology (Williston Park, NY)
https://read.qxmd.com/read/30474102/pros-and-cons-of-dietary-strategies-popular-among-cancer-patients
#20
REVIEW
Suzanna Maria Zick, Detrick Snyder, Donald I Abrams
As many as 48% of cancer patients pursue popular diets, including the alkaline, Paleolithic, ketogenic, vegan, and macrobiotic diets, with the hope that they will improve survival and prevent recurrence. These diets have positive aspects consistent with the dietary guidelines proposed by the American Cancer Society (ACS) and the American Institute for Cancer Research (AICR). All of the diets emphasize eating vegetables, all but the ketogenic diet encourage eating fruit, and all but the vegan diet limit refined grains and alcohol...
November 15, 2018: Oncology (Williston Park, NY)
journal
journal
29689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"